• Drugs Made In America Acquisition Corp. signed a merger agreement on April 29, 2026, with Power Analytics Global Corp., an artificial intelligence, advanced analytics, and quantum-resistant security business.
• Transaction targets a $1 billion enterprise valuation for Power Analytics, subject to a valuation schedule tied to verified, signed revenue contracts delivered by closing.
• Agreement includes a $300 million floor valuation, below which parties can renegotiate or terminate.
• Post-close ownership expected to be about 90% for legacy Power Analytics shareholders, about 10% for existing DMAA shareholders, before any PIPE or other closing issuances.
• Deal terms contemplate a $30 million minimum cash target at closing, with flexibility to close as low as $15 million with corresponding adjustments to valuation and ownership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-052324), on May 05, 2026, and is solely responsible for the information contained therein.